JNJ · News · 20260917N

Portfolio Reshaping (M&A / Divestiture)

JOHNSON & JOHNSON · 2026-09-17 · Importance 37 · Surprise 42 · In source text

Johnson & Johnson sold the assets of its Laminar left atrial appendage-closure technology to Jaguar LAA, a newly formed private company. The transaction indicates J&J is exiting the LAA-closure market after suspending Laminar’s pivotal trial because of potential post-implant unwrapping and leaks. Jaguar LAA was formed with Santé Ventures and Laminar management and plans to continue development and pursue U.S. Food and Drug Administration approval.

Key facts

• Talon Private Wealth LLC grew its holdings in Johnson and Johnson by 89.5% and owned 10,588 shares after purchasing an additional 5,002 shares during the undefined quarter. source
• Johnson & Johnson is exiting the left atrial appendage (LAA) closure market and sold the assets of its Laminar technology to Jaguar LAA. source
• Jaguar LAA was formed in partnership with Santé Ventures and Laminar's management to continue developing the LAA closure technology and pursue FDA approval. source
• Johnson & Johnson suspended a pivotal trial for the Laminar device due to potential post-implant unwrapping and leaks. source
• Blue Edge Capital LLC reduced its stake in Johnson and Johnson by 18.7% and owned 15,069 shares after selling 3,464 shares during the period. source
• U S Wealth Group LLC raised its stake in Johnson and Johnson by 15.1% and owned 17,259 shares after purchasing an additional 2,266 shares during the period. source
• Core Capital Management and Research inc. bought 4,002 shares of Johnson and Johnson stock valued at approximately $1,087,000. source
• National Pension Service owned 5,226,968 shares of Johnson and Johnson after purchasing an additional 67,484 shares during the second quarter, constituting a holding the article describes as $1.33 billion. source

Impact estimates